No association between LDL receptor and CETP genetic variants and atorvastatin response in Jordanian hyperlipidemic patients.

Q2 Pharmacology, Toxicology and Pharmaceutics

Drug metabolism and personalized therapy Pub Date : 2022-12-01 DOI:10.1515/dmpt-2021-0177

Malek Zihlif, Suhad Otoum, Mohammad Al Shhab, Zaid Almadani, Monther Momani, Hussam Alhawari, Esraa Jibrini, Yazun Jarrar, Hamzeh Al-Ameer, Amer Imraish

{"title":"No association between LDL receptor and CETP genetic variants and atorvastatin response in Jordanian hyperlipidemic patients.","authors":"Malek Zihlif, Suhad Otoum, Mohammad Al Shhab, Zaid Almadani, Monther Momani, Hussam Alhawari, Esraa Jibrini, Yazun Jarrar, Hamzeh Al-Ameer, Amer Imraish","doi":"10.1515/dmpt-2021-0177","DOIUrl":null,"url":null,"abstract":"Objectives: Atorvastatin is commonly used medication to achieve low levels of low-density lipoproteins (LDL). Cholesteryl ester transfer protein (CETP) and LDL receptor (LDLR) genetic variants can affect the cholesterol transport and hence may affect on atorvastatin response. This study aimed to investigate the influence of LDLR AvaII, CETP TaqIb, and Rs1532624 on the efficacy of 20 mg atorvastatin among Jordanian hyperlipidemic patients.Methods: One hundred and 50 blood samples were collected from hyperlipidemic patients in the University of Jordan Hospital. Polymerase chain reaction-restriction fragment length polymorphism was used for genotyping of LDLR AvaII and CETP TaqIb genetic variants. The genotyping of CETP Rs1532624 variant was done by Sanger DNA-Sequencing.Results: LDLR AvaII and CETP TaqIb and Rs1532624 variants showed a significant (p value < 0.05) association with the baseline of the LDL at the time of diagnoses. On the other hand, none of the tested genetic variants showed a significant (p value>0.05) association with LDL reduction after atorvastatin therapy.Conclusions: Results demonstrated a significant association between the LDLR AvaII and CETP TaqIb, and Rs1532624 genetic variants with the LDL baseline level. However, the atorvastatin therapy among hyperlipidemic patients of Jordanian origin was not affected by any of the tested variants.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"37 4","pages":"369-374"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug metabolism and personalized therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/dmpt-2021-0177","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Atorvastatin is commonly used medication to achieve low levels of low-density lipoproteins (LDL). Cholesteryl ester transfer protein (CETP) and LDL receptor (LDLR) genetic variants can affect the cholesterol transport and hence may affect on atorvastatin response. This study aimed to investigate the influence of LDLR AvaII, CETP TaqIb, and Rs1532624 on the efficacy of 20 mg atorvastatin among Jordanian hyperlipidemic patients.

Methods: One hundred and 50 blood samples were collected from hyperlipidemic patients in the University of Jordan Hospital. Polymerase chain reaction-restriction fragment length polymorphism was used for genotyping of LDLR AvaII and CETP TaqIb genetic variants. The genotyping of CETP Rs1532624 variant was done by Sanger DNA-Sequencing.

Results: LDLR AvaII and CETP TaqIb and Rs1532624 variants showed a significant (p value < 0.05) association with the baseline of the LDL at the time of diagnoses. On the other hand, none of the tested genetic variants showed a significant (p value>0.05) association with LDL reduction after atorvastatin therapy.

Conclusions: Results demonstrated a significant association between the LDLR AvaII and CETP TaqIb, and Rs1532624 genetic variants with the LDL baseline level. However, the atorvastatin therapy among hyperlipidemic patients of Jordanian origin was not affected by any of the tested variants.

查看原文本刊更多论文

约旦高脂血症患者LDL受体和CETP基因变异与阿托伐他汀反应之间无关联

目的:阿托伐他汀是实现低密度脂蛋白(LDL)水平的常用药物。胆固醇酯转移蛋白(CETP)和低密度脂蛋白受体(LDLR)基因变异可影响胆固醇转运，从而影响阿托伐他汀反应。本研究旨在探讨LDLR AvaII、CETP TaqIb和Rs1532624对约旦高脂血症患者20mg阿托伐他汀疗效的影响。方法:采集约旦大学医院高脂血症患者血样150份。采用聚合酶链反应-限制性片段长度多态性对LDLR AvaII和CETP TaqIb遗传变异进行基因分型。采用Sanger DNA-Sequencing对CETP Rs1532624变异进行基因分型。结果:LDLR AvaII、CETP TaqIb和Rs1532624变异与阿托伐他汀治疗后LDL降低有显著相关性(p值0.05)。结论:结果表明LDLR AvaII和CETP TaqIb以及Rs1532624基因变异与LDL基线水平存在显著相关性。然而，在约旦血统的高脂血症患者中，阿托伐他汀治疗不受任何测试变异的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug metabolism and personalized therapy Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)

CiteScore

2.30

自引率

0.00%

发文量

期刊介绍： Drug Metabolism and Personalized Therapy (DMPT) is a peer-reviewed journal, and is abstracted/indexed in relevant major Abstracting Services. It provides up-to-date research articles, reviews and opinion papers in the wide field of drug metabolism research, covering established, new and potential drugs, environmentally toxic chemicals, the mechanisms by which drugs may interact with each other and with biological systems, and the pharmacological and toxicological consequences of these interactions and drug metabolism and excretion. Topics: drug metabolizing enzymes, pharmacogenetics and pharmacogenomics, biochemical pharmacology, molecular pathology, clinical pharmacology, pharmacokinetics and drug-drug interactions, immunopharmacology, neuropsychopharmacology.